이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports (PSMA-LLM-cTNM)

2026년 7월 15일 업데이트: Qi Lin, MD, First Affiliated Hospital of Wenzhou Medical University

Large Language Model-Assisted Imaging cTNM Staging Annotation and Uncertainty Recognition for Prostate Cancer Based on Chinese PSMA PET/CT Reports

This observational study will develop and validate a large language model-assisted workflow for imaging cTNM staging annotation and uncertainty recognition in prostate cancer using Chinese PSMA PET/CT report texts generated during routine clinical care. The study will use de-identified report texts and necessary baseline clinical information only. No additional imaging examination, blood test, treatment, or follow-up visit will be assigned for this study.

The main objective is to evaluate whether a locally or institutionally controlled large language model can identify report-derived imaging cT, cN, and cM categories, extract supporting evidence from the original report, and recognize uncertainty expressions. Model performance will be assessed using an internal independent validation set, external validation reports from two collaborating hospitals, and a prospective validation set of 100 consecutive routine PSMA PET/CT reports. A human-AI comparison will also be performed using physicians from urology and imaging-related specialties with different seniority levels.

연구 개요

상태

아직 모집하지 않음

정황

상세 설명

This is a multicenter observational diagnostic accuracy validation study based on Chinese PSMA PET/CT report texts from patients with prostate cancer or suspected prostate cancer. The study is not designed to evaluate a drug, device, surgical procedure, or imaging intervention. PSMA PET/CT examinations will be performed as part of routine clinical care, and the study will only analyze de-identified report texts and necessary baseline information after the reports have been finalized.

The study consists of retrospective and prospective components. Retrospectively, approximately 4,000 PSMA PET/CT reports from the First Affiliated Hospital of Wenzhou Medical University will be systematically annotated to construct a research database. An internal independent validation set of 300 reports, not used for model development or prompt optimization, will be used to evaluate the performance of the large language model. The reference standard for this 300-report validation set will be established by two experienced urologists through joint annotation, with adjudication by a nuclear medicine expert when needed. External validation will be performed using 110 de-identified reports from the First Affiliated Hospital of Ningbo University and 102 de-identified reports from Liuzhou People's Hospital. In addition, after ethics approval, 100 consecutive routine PSMA PET/CT reports from the First Affiliated Hospital of Wenzhou Medical University will be prospectively included to evaluate the accuracy and operational stability of the frozen model and prompt versions.

The large language model workflow will be deployed locally or in an institutionally controlled environment. The model will be instructed to generate structured JSON outputs, including cT_report, cN_report, cM_report, cT_uncertain, cN_uncertain, cM_uncertain, evidence_T, evidence_N, and evidence_M. The target task is report-derived imaging cTNM staging annotation, not pathological TNM staging or overall AJCC stage grouping. The model output will be used only for research evaluation and methodological analysis and will not be used for clinical diagnosis, treatment decision-making, or patient notification.

A human-AI comparison will be conducted on the 300-report internal validation set. Eight human evaluators from urology and imaging-related specialties, including trainees, residents, attending physicians, and associate chief physicians, will independently annotate the reports before and after learning the annotation manual. Annotation time will be recorded for each round. The performance of human evaluators and the large language model will be compared against the expert consensus reference standard.

The main outcome will be the accuracy of the large language model in identifying cT, cN, and cM categories from Chinese PSMA PET/CT reports. Secondary outcomes will include precision, recall, F1-score, macro-F1, micro-F1, complete cTNM triplet matching rate, uncertainty recognition performance, evidence extraction quality, human-AI comparison results, annotation time, external validation performance, prospective validation performance, and error type distribution. Error analysis will focus on local tumor extent, regional versus non-regional lymph node boundaries, bone and visceral metastasis recognition, equivocal wording, treatment-related context, benign or inflammatory alternatives, and lesions not attributable to prostate cancer.

연구 유형

관찰

등록 (추정된)

4600

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Zhejiang
      • Wenzhou, Zhejiang, 중국
        • The First Affiliated Hospital of Wenzhou Medical University
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

The study population consists of male patients aged 18 years or older with clinically diagnosed, pathologically diagnosed, or clinically suspected prostate cancer who underwent PSMA PET/CT as part of routine clinical care. The study will include de-identified Chinese PSMA PET/CT report texts from the First Affiliated Hospital of Wenzhou Medical University, the First Affiliated Hospital of Ningbo University, and Liuzhou People's Hospital, as well as a prospective set of 100 consecutive routine PSMA PET/CT reports from the First Affiliated Hospital of Wenzhou Medical University.

설명

Inclusion Criteria:

  1. Male patients aged 18 years or older.
  2. Patients with clinically diagnosed, pathologically diagnosed, or clinically suspected prostate cancer.
  3. Patients who underwent PSMA PET/CT for initial staging, recurrence assessment, treatment response evaluation, metastatic assessment, or other clinical purposes during routine care.
  4. Complete or basically complete Chinese PSMA PET/CT report text is available, including imaging findings and/or diagnostic impression.
  5. The report text contains information that can be used to evaluate at least one target field, such as local prostate lesion, regional lymph nodes, non-regional lymph nodes, bone metastasis, visceral metastasis, or uncertainty expressions.
  6. The research data can be de-identified and replaced by a study identification number before analysis.

Exclusion Criteria:

  1. PSMA PET/CT reports unrelated to prostate cancer, or reports clearly irrelevant to the research task.
  2. Reports with severely missing, unreadable, or unavailable main text, imaging findings, or diagnostic impression.
  3. Reports that cannot be adequately de-identified or contain residual direct personal identifiers that cannot be safely removed.
  4. Duplicate records, repeated exports of the same examination, or records for which the unique report version cannot be confirmed.
  5. Reports judged by the research team to be of insufficient quality for manual annotation, model evaluation, or statistical analysis.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
PSMA PET/CT Report Text Validation Cohort
Patients with prostate cancer or suspected prostate cancer who underwent PSMA PET/CT as part of routine clinical care. De-identified Chinese PSMA PET/CT report texts and necessary baseline information will be used for manual annotation, large language model-assisted imaging cTNM staging annotation, uncertainty recognition, internal validation, external validation, prospective validation, and human-AI comparison. No additional examination, treatment, or follow-up will be assigned for this study.
A locally or institutionally controlled large language model workflow will analyze de-identified Chinese PSMA PET/CT report texts and generate structured outputs for report-derived imaging cTNM staging annotation, uncertainty recognition, and supporting evidence extraction. This workflow is used only for research evaluation and methodological analysis. It will not assign any examination, treatment, medication, procedure, or follow-up to participants, and it will not guide clinical diagnosis or treatment decisions.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Accuracy of LLM-Assisted Imaging cTNM Staging Annotation
기간: After freezing the model and prompt versions, through completion of internal, external, and prospective validation, up to 18 months
The primary outcome is the accuracy of the large language model in identifying report-derived imaging cT, cN, and cM categories from de-identified Chinese PSMA PET/CT report texts. The LLM-generated cT_report, cN_report, and cM_report will be compared with the expert consensus reference standard. Accuracy, precision, recall, F1-score, macro-F1, micro-F1, complete cTNM triplet matching rate, and confusion matrices will be calculated in the internal 300-report validation set, external validation sets, and prospective 100-report validation set.
After freezing the model and prompt versions, through completion of internal, external, and prospective validation, up to 18 months

2차 결과 측정

결과 측정
측정값 설명
기간
Component-Level Accuracy of LLM-Based Uncertainty Recognition
기간: After freezing the model and prompt versions, through completion of all validation analyses, up to 18 months.

This outcome measures the component-level accuracy of the large language model in recognizing uncertainty labels for report-derived imaging cTNM staging. The LLM-generated cT_uncertain, cN_uncertain, and cM_uncertain labels will be compared with the expert consensus reference standard. Accuracy will be calculated as the number of correctly classified uncertainty labels divided by the total number of component-level uncertainty labels across all reports. The three uncertainty components will be aggregated into one percentage value.

中文对应

After freezing the model and prompt versions, through completion of all validation analyses, up to 18 months.
Complete cTNM Triplet Matching Rate for Human Evaluators and the LLM
기간: During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
This outcome measures the proportion of reports for which the complete report-derived imaging cTNM triplet assigned by human evaluators and by the large language model exactly matches the expert consensus reference standard. A report will be counted as correct only when all three components, cT_report, cN_report, and cM_report, are correct. The result will be reported as the percentage of reports with complete cTNM triplet agreement. Results will be summarized separately for pre-training human annotation, post-training human annotation, and LLM batch inference.
During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
Annotation Time per Report for Human Evaluators and the LLM
기간: During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
This outcome measures the mean time required to complete report-derived imaging cTNM annotation per report. For human evaluators, annotation time will be recorded during the annotation rounds and divided by the number of annotated reports. For the LLM workflow, batch inference time will be divided by the number of processed reports. Results will be reported separately for pre-training human annotation, post-training human annotation, and LLM batch inference.
During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 17일

기본 완료 (추정된)

2027년 6월 30일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2026년 6월 30일

QC 기준을 충족하는 최초 제출

2026년 7월 15일

처음 게시됨 (실제)

2026년 7월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 15일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant-level data will not be shared. The study data consist of de-identified Chinese PSMA PET/CT report texts and necessary baseline clinical information generated during routine clinical care. Although direct identifiers will be removed, the free-text report data may still carry a potential risk of re-identification. Therefore, individual-level raw data will not be made publicly available. Study findings will be reported in aggregate form. De-identified summary data or analysis methods may be made available upon reasonable request and with approval from the ethics committee and the institutional data governance authority, when applicable.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

전립선암에 대한 임상 시험

Large Language Model-Assisted Report Annotation에 대한 임상 시험

3
구독하다